ArticleCureus2025
Malignant Priapism, an Ominous Sign With Dismal Prognosis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant priapism is a rare and serious manifestation that results from advanced malignancy. It is caused by the infiltration of tumour cells into the penile tissue. Genitourinary cancers are the most common cause, especially prostatic adenocarcinoma. It indicates widespread metastatic disease and is associated with a poorer prognosis. It presents as a prolonged, painful erection that is not related to sexual activity and is often refractory to conventional treatments. It is rare and usually diagnosed late in the disease course. We report a 70-year-old male who underwent transurethral resection of the prostate (TURP) and bilateral orchidectomy for locally advanced prostatic adenocarcinoma and lost to follow-up. He presented six months later with painful priapism, multiple penile nodules, and acute urinary retention. Imaging studies, including high-resolution penile ultrasound and 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) scan, confirmed multiple penile metastatic deposits. Despite initial pain management with nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids, his refractory symptoms necessitated a total penectomy with perineal urethrostomy. Histopathological examination confirmed infiltrating carcinomatous deposits. Unfortunately, despite aggressive management, the patient eventually succumbed to the disease. This report emphasizes the aggressive character of penile metastases from prostate cancer, the challenges in diagnosis and treatment, and the need for a multidisciplinary approach. Early recognition and palliative strategies are essential for maximizing the quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.